Table. 10.
Table. 10.
Notable outcomes of selected RCT studies assessing the effects of probiotics on GI diseases
| Reference | Gut microbiota assessment | Outcomes of GI symptoms |
|---|---|---|
| Macnaughtan et al., 2020, UK | - | - |
| Giannetti et al., 2017, Italy | - | In IBS, |
| Cappello et al., 2013 Italy (Rome) |
- | - |
| Cudmore et al., 2017, Ireland | - | Symptoms of constipation improved |
| Fujimori et al., 2009, Japan | - | Emotional function increased in the probiotic and synbiotic groups |
| Gomi et al., 2018, Japan | - | The YIT10347 group had significantly higher relief rates of overall gastrointestinal symptoms, upper gastrointestinal symptoms, flatus, and diarrhea than the placebo group |
| Francavilla et al., 2019, Italy | ·Using plate counts and 16S rRNA gene-based analysis ·Fecal samples (5 g) were mixed with 45 mL of sterilized physiological solution and homogenized. Viable bacterial cells were counted as described by De Angelis et al. ·To determine the identities of bacteria, sequences were first queried using a distributed BLASTn.NET algorithm24 against 16S bacterial sequences derived from NCBI. |
- |
| Radvar et al., 2020, Iran | - | Body weight decreased in the synbiotic and placebo groups |
| Aroniadis et al., 2019, USA | 16S rRNA sequencing | - |
| Chen et al., 2016, Taiwan | - | Complaints of abdominal pain, abdominal bloating, excessive passage of gas, foul smell of flatulence, belching, abdominal noises, and heartburn were significantly improved in the entire sample |
| Dapoigny et al., 2012, France | Extraction of total bacterial DNA (QIAamp Fast DNA Stool Mini Kit, QIAGEN), the presence of |
A decrease in the abdominal pain severity score was observed with LCR35 |
| Choi et al., 2015, Korea | - | The abdominal pain/discomfort score in treatment group 4 was more prominently improved compared with that of the placebo group In patients with constipation-predominant IBS, the improvements in stool frequency and consistency were significantly higher in treatment groups 4 and 1, respectively, than those in the placebo group There were more favorable tendencies of effects on bloating in all treatment groups than in the placebo group |
| El-Salhy et al., 2020, Norway | 16S rRNA gene sequencing | - |
| Ding et al., 2016, China | - | During the intervention period, patients who were treated with the synbiotic exhibited increased stool frequency, improved stool consistency, decreased colonic transit time, and improved constipation-related symptoms |
| Ohigashi et al., 2011, Japan | - | Defecation frequency, anal pain, and Wexner score were significantly poorer in the rectal group than in the colonic group |
| Ringel-Kulka et al., 2011, USA | Quantitative real-time polymerase chain reaction of fecal samples | Abdominal bloating improved in the probiotic group compared with the placebo group at 4 and 8 weeks |
| Dimidi et al., 2019, UK | Quantitative polymerase chain reaction | - |
| Šmid et al., 2016, Slovenia & Croatia | - | Significant improvements in bloating severity, satisfaction with bowel movements |
| Golkhalkhali et al., 2018, Malaysia | - | Nausea, vomiting, and diarrhea significantly improved in the treatment group |
| Theodoropoulos et al., 2016, Netherlands | - | Differences in the EORTC QLQ-C30 “diarrhea” domain score from baseline were better after synbiotic administration after 3 ( |
| Nobutani et al., 2017, Japan | ·Purified DNA was used as a template for the following two-step polymerase chain reaction. ·Fecal microbiota was measured using fecal bacterial 16S rDNA V4-V6 region-targeted pyrosequencing. |
CP2305 favorably changed the fecal characteristics compared with placebo among patients with IBS with either diarrhea or constipation subtypes |
| Drisko et al., 2006, USA | - | Significant improvements in pain were observed ( |
RCT, randomized controlled trial; GI, gastrointestinal; IBS, irritable bowel syndrome; NCBI, National Center for Biotechnology Information; QoL, quality of life; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer’s 30-item QoL questionnaire version 30; -, not available.
Prev Nutr Food Sci 2024;29:237~255 https://doi.org/10.3746/pnf.2024.29.3.237
© Prev. Nutr. Food Sci.